Afficher la notice abrégée

dc.contributor.authorColl-Vinent, B
dc.contributor.authorMartín, A
dc.contributor.authorSánchez, J
dc.contributor.authorTamargo, J
dc.contributor.authorSuero, C
dc.contributor.authorMalagón, F
dc.contributor.authorVarona, M
dc.contributor.authorCancio, M
dc.contributor.authorSánchez, S
dc.contributor.authorCarbajosa, J
dc.contributor.authorRíos, J
dc.contributor.authorCasanova, G
dc.contributor.authorRáfols, C
dc.contributor.authorDel Arco, C
dc.contributor.authorAgud, M
dc.contributor.authorBajo Bajo, Ángel Ascensino 
dc.date.accessioned2024-12-10T12:19:59Z
dc.date.available2024-12-10T12:19:59Z
dc.date.issued2017
dc.identifier.citationColl-Vinent et al Benefits of Stroke Prophylaxis in Emergency Rooms. Stroke. 2017;48:1344-1352. DOI: 10.1161/STROKEAHA.116.014855es_ES
dc.identifier.issn1524-4628
dc.identifier.urihttp://hdl.handle.net/10366/161008
dc.description.abstract[EN] Background and Purpose—Long-term benefits of initiating stroke prophylaxis in the emergency department (ED) are unknown. We analyzed the long-term safety and benefits of ED prescription of anticoagulation in atrial fibrillation patients. Methods—Prospective, multicenter, observational cohort of consecutive atrial fibrillation patients was performed in 62 Spanish EDs. Clinical variables and thromboprophylaxis prescribed at discharge were collected at inclusion. Follow-up at 1 year post-discharge included data about thromboprophylaxis and its complications, major bleeding, and death; risk was assessed with univariate and bivariate logistic regression models. Results—We enrolled 1162 patients, 1024 (88.1%) at high risk according to CHA2DS2-VASc score. At ED discharge, 935 patients (80.5%) were receiving anticoagulant therapy, de novo in 237 patients (55.2% of 429 not previously treated). At 1 year, 48 (4.1%) patients presented major bleeding events, and 151 (12.9%) had died. Anticoagulation first prescribed in the ED was not related to major bleeding (hazard ratio, 0.976; 95% confidence interval, 0.294–3.236) and was associated with a decrease in mortality (hazard ratio, 0.398; 95% confidence interval, 0.231–0.686). Adjusting by the main clinical and sociodemographic characteristics, concomitant antiplatelet treatment, or destination (discharge or admission) did not affect the results. Conclusions—Prescription of anticoagulation in the ED does not increase bleeding risk in atrial fibrillation patients at high risk of stroke and contributes to decreased mortality.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Heart Association, Inc., by Wolters Kluwer Health, Inc.es_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAnticoagulantses_ES
dc.subjectAtrial fibrillationes_ES
dc.subjectHemorragees_ES
dc.subjectMortality strokees_ES
dc.titleBenefits of emergency departments’ contribution to stroke prophylaxis in atrial fibrillation the EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation)es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1161/STROKEAHA.116.01485es_ES
dc.identifier.doiDOI: 10.1161/STROKEAHA.116.014855
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.journal.titleStrokees_ES
dc.volume.number48es_ES
dc.issue.number5es_ES
dc.page.initial1344es_ES
dc.page.final1352es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional